Yuqi Qiu1, Diane M Jacobs1, Karen Messer1, David P Salmon1, Howard H Feldman2. 1. From the Department of Family Medicine and Public Health (Y.Q., K.M.), Department of Neurosciences (D.M.J., D.P.S., H.H.F.), and Shiley-Marcos Alzheimer's Disease Research Center (D.M.J., D.P.S., H.H.F.), University of California, San Diego, La Jolla. 2. From the Department of Family Medicine and Public Health (Y.Q., K.M.), Department of Neurosciences (D.M.J., D.P.S., H.H.F.), and Shiley-Marcos Alzheimer's Disease Research Center (D.M.J., D.P.S., H.H.F.), University of California, San Diego, La Jolla. hhfeldman@ucsd.edu.
Abstract
OBJECTIVE: To identify heterogeneity in cognitive profiles of patients with probable Alzheimer disease (AD) who have mild to moderate dementia and satisfy inclusion and exclusion criteria for a typical AD clinical trial, and to determine whether cognitive profiles are systematically related to the clinical course and neuropathologic features of the disease. METHODS: Neuropsychological test data from patients with mild to moderate probable AD (n = 4,711) were obtained from the National Alzheimer's Coordinating Center. Inclusion and exclusion criteria usually used in AD clinical trials were applied. Principal component analysis and model-based clustering were used to identify cognitive profiles in a subset of patients with autopsy-verified AD (n = 800) and validated in the overall (nonautopsy) sample and an independent cohort with similar test data. Relationships between cognitive profile, clinical characteristics, and rate of decline were examined with mixed-effects models. RESULTS: In the autopsy-confirmed sample, 79.6% of patients had a typical AD cognitive profile (greater impairment of episodic memory than other cognitive functions), and 20.4% had an atypical profile (comparable impairment across cognitive domains). Similar results were obtained in the overall (typical 79.8%, atypical 20.2%) and validation (typical 71.8%, atypical 28.2%) samples. Atypicality was associated with younger age, male sex, lower probability of APOE ε4, less severe global dementia, higher depression scores, lower Braak stage at autopsy, and slower cognitive decline. CONCLUSION: We can reliably identify distinct cognitive profiles among patients with clinically diagnosed probable AD that are associated with tangle pathology and with different rates of decline. This may have implications for clinical trials in AD, especially therapies targeting tau.
OBJECTIVE: To identify heterogeneity in cognitive profiles of patients with probable Alzheimer disease (AD) who have mild to moderate dementia and satisfy inclusion and exclusion criteria for a typical AD clinical trial, and to determine whether cognitive profiles are systematically related to the clinical course and neuropathologic features of the disease. METHODS: Neuropsychological test data from patients with mild to moderate probable AD (n = 4,711) were obtained from the National Alzheimer's Coordinating Center. Inclusion and exclusion criteria usually used in AD clinical trials were applied. Principal component analysis and model-based clustering were used to identify cognitive profiles in a subset of patients with autopsy-verified AD (n = 800) and validated in the overall (nonautopsy) sample and an independent cohort with similar test data. Relationships between cognitive profile, clinical characteristics, and rate of decline were examined with mixed-effects models. RESULTS: In the autopsy-confirmed sample, 79.6% of patients had a typical AD cognitive profile (greater impairment of episodic memory than other cognitive functions), and 20.4% had an atypical profile (comparable impairment across cognitive domains). Similar results were obtained in the overall (typical 79.8%, atypical 20.2%) and validation (typical 71.8%, atypical 28.2%) samples. Atypicality was associated with younger age, male sex, lower probability of APOE ε4, less severe global dementia, higher depression scores, lower Braak stage at autopsy, and slower cognitive decline. CONCLUSION: We can reliably identify distinct cognitive profiles among patients with clinically diagnosed probable AD that are associated with tangle pathology and with different rates of decline. This may have implications for clinical trials in AD, especially therapies targeting tau.
Authors: S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg Journal: Neurology Date: 1991-04 Impact factor: 9.910
Authors: Nienke M E Scheltens; Francisca Galindo-Garre; Yolande A L Pijnenburg; Annelies E van der Vlies; Lieke L Smits; Teddy Koene; Charlotte E Teunissen; Frederik Barkhof; Mike P Wattjes; Philip Scheltens; Wiesje M van der Flier Journal: J Neurol Neurosurg Psychiatry Date: 2015-03-17 Impact factor: 10.154
Authors: Paul K Crane; Emily Trittschuh; Shubhabrata Mukherjee; Andrew J Saykin; R Elizabeth Sanders; Eric B Larson; Susan M McCurry; Wayne McCormick; James D Bowen; Thomas Grabowski; Mackenzie Moore; Julianna Bauman; Alden L Gross; C Dirk Keene; Thomas D Bird; Laura E Gibbons; Jesse Mez Journal: Alzheimers Dement Date: 2017-06-15 Impact factor: 21.566
Authors: D S Knopman; S T DeKosky; J L Cummings; H Chui; J Corey-Bloom; N Relkin; G W Small; B Miller; J C Stevens Journal: Neurology Date: 2001-05-08 Impact factor: 9.910
Authors: Josephine Barnes; Bradford C Dickerson; Chris Frost; Lize C Jiskoot; David Wolk; Wiesje M van der Flier Journal: Alzheimers Dement Date: 2015-04-24 Impact factor: 21.566
Authors: Julie E Davidson; Michael C Irizarry; Bethany C Bray; Sally Wetten; Nicholas Galwey; Rachel Gibson; Michael Borrie; Richard Delisle; Howard H Feldman; Ging-Yuek Hsiung; Luis Fornazzari; Serge Gauthier; Danilo Guzman; Inge Loy-English; Ron Keren; Andrew Kertesz; Peter St George-Hyslop; John Wherrett; Andreas U Monsch Journal: J Int Neuropsychol Soc Date: 2009-12-04 Impact factor: 2.892
Authors: Bruno Dubois; Howard H Feldman; Claudia Jacova; Steven T Dekosky; Pascale Barberger-Gateau; Jeffrey Cummings; André Delacourte; Douglas Galasko; Serge Gauthier; Gregory Jicha; Kenichi Meguro; John O'brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Yaakov Stern; Pieter J Visser; Philip Scheltens Journal: Lancet Neurol Date: 2007-08 Impact factor: 44.182
Authors: Sandra Weintraub; Lilah Besser; Hiroko H Dodge; Merilee Teylan; Steven Ferris; Felicia C Goldstein; Bruno Giordani; Joel Kramer; David Loewenstein; Dan Marson; Dan Mungas; David Salmon; Kathleen Welsh-Bohmer; Xiao-Hua Zhou; Steven D Shirk; Alireza Atri; Walter A Kukull; Creighton Phelps; John C Morris Journal: Alzheimer Dis Assoc Disord Date: 2018 Jan-Mar Impact factor: 2.703
Authors: D Puttaert; N Coquelet; V Wens; P Peigneux; P Fery; A Rovai; N Trotta; N Sadeghi; T Coolen; J-C Bier; S Goldman; X De Tiège Journal: Sci Rep Date: 2020-12-15 Impact factor: 4.379